FDA grants final approval for Teva's Ribavirin (Hepatitis C Infection)

FDA grants final approval for Teva's Ribavirin
Israel Business Arena - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ; TASE: TEVA ) has announced that the US Food and Drug Administration (FDA) has granted final approval for the company's abbreviated new drug application (ANDA) for Ribavirin tablets, 200 mg. Teva's

Pharmacy Benefit
Managed Healthcare Executive - No wonder metabolic syndrome is called syndrome X. Instead of being recognized as a separate disease, it is considered a constellation of many conditions. "The biggest problem is a failure to address the underlying problem insulin resistance," says

Study: 200 proteins show liver diseases
Science Daily - NAVARRA, Spain, Dec. 13 (UPI) -- A University of Navarra biochemist, Enrique Santamaria Martinez, has identified more than 200 proteins that might be indicators of liver disease. Related Headlines Liver transplants: Not for all CF patients (November

Texas scientists discover how a hepatitis C protein promotes liver
EurekAlert - GALVESTON, Texas--Scientists at the University of Texas Medical Branch at Galveston (UTMB) have identified a key biochemical connection between the hepatitis C virus and liver cancer. The molecular mechanism is similar to the one that links the human

Diazyme Receives FDA 510(K) Approval for Enzymatic Total Bile Acids
Market Wire - SAN DIEGO, CA -- (MARKET WIRE) -- 12/22/2005 -- Diazyme Laboratories, a company that applies its proprietary enzyme technologies to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S

FDA gives Fast Track status to Vertex s Hepatitis C treatment
Mass High Tech - The U.S. Food and Drug Administration has granted Fast Track designation to VX-950, an investigational oral hepatitis C virus (HCV) treatment being developed by Vertex Pharmaceuticals Inc. According to Vertex officials, the FDA granted the Fast Track